Galactosemia is an inborn error of metabolism due to impaired degradation of galactose. The disease was first described in 1917, and defective galactose metabolism was explained as the cause in the 1950s. If not recognized and treated promptly, affected infants may develop significant morbidity within days of birth. Newborn screening tests in developed countries have helped identify affected infants early, though providers must maintain a high index of suspicion in ill newborns as feeding intolerance, hepatomegaly, lethargy, coagulopathy, and renal dysfunction may occur within the first few days of life even before newborn screening tests have been finalized.
The GALT gene on chromosome 9p13 encodes for galactose-1-phosphate uridylyltransferase which is responsible for metabolizing galactose-1-phosphate to UDP-galactose. Deficiency of the enzyme leads to classic galactosemia. The GALK1 gene on chromosome 17q24 encodes for galactokinase which is responsible for metabolizing galactose to galactose-1-phosphate. The GALE gene on chromosome 1p36-p35 encodes for UDP-galactose 4-epimerase which is responsible for metabolizing UDP-galactose to UDP-glucose for use in glycogenesis. Inheritance is autosomal recessive so both parents must be carriers and offspring have a 25% chance of having clinical symptoms. Carriers do not typically demonstrate symptoms.
Duarte galactosemia is a variant of galactosemia due to diminished galactose-1-phosphate uridylyltransferase enzyme activity (typically around 14% to 25%). Individuals born with Duarte variant galactosemia are thought to be asymptomatic with or without dietary intervention, and the consensus among health professionals is that affected individuals do not require treatment. However, some reports to the contrary exist, and no adequately powered study has been completed to verify or refute possible effects diminished GALT activity on long-term neurodevelopmental outcomes. Duarte galactosemia may or may not be detected by newborn screening testing.
Approximately 1 in 19,000 to 44,000 infants in Europe and the United States have galactosemia, but the incidence is highly variable based on ethnic background with the highest incidence in the Irish Traveler population of approximately 1 in 480. Inheritance is autosomal recessive.
The disaccharide lactose found in breastmilk and most infant formulas is metabolized to the monosaccharides glucose and galactose. In galactosemia, the enzymes needed for further galactose metabolism are deficient. Classic galactosemia is caused by galactose-1-phosphate uridylyltransferase (GALT) deficiency, whereas galactokinase and UDP-galactose epimerase deficiencies may cause similar clinical consequences by disrupting the normal galactose metabolism (see figure). Ultimately, levels of galactose-1-phosphate reach toxic levels and galactose may be alternatively reduced to its sugar alcohol form, galactitol. Galactitol is thought to cause direct damage to tissues leading to hepatomegaly, cirrhosis, renal failure, feeding intolerance, vomiting, hypoglycemia, seizure, lethargy, intellectual impairment, and cataracts. Untreated, mortality is at least 75%. Even when treated from a young age, sequelae may include cognitive or behavioral impairment, speech difficulties, low bone mineral density, ataxia or tremors, and primary ovarian insufficiency or failure in most girls.
Increased levels of galactose-1-phosphate due to blockage of the typical metabolic pathway are suspected to lead to alternative metabolism and direct tissue damage. Elevated levels of galactitol (galactose reduced to its sugar alcohol form) have been found in the urine of patients with galactosemia as well as tissues with evidence of damage in galactosemia. Galactose may also be oxidized to galactonate which may be a less toxic metabolite compared to accumulated galactitol.
Infants with galactosemia will typically present within the first few days of life with jaundice, hepatomegaly, lethargy, and severe feeding intolerance once there is any exposure to dietary galactose in the form of breastmilk or most standard infant formulas. Additional findings may include poor weight gain, renal failure, coagulopathy, hypoglycemia, seizures, cerebral edema, cataracts, vitreous hemorrhage, neutropenia, and Escherichia coli sepsis. Once diagnosed, long-term follow-up includes monitoring for cognitive and behavioral impairment, fine and gross motor delays, speech difficulties, low bone mineral density, ataxia or tremor, and primary ovarian insufficiency/failure.
Newborn screening tests will identify most cases of galactosemia in developed countries. Testing evaluates for pertinent enzyme activity levels so diagnosis can be made even if testing is done before the introduction of galactose in the diet. However, if a blood transfusion has occurred before newborn screening tests, a case may be misinterpreted as being normal due to the presence of normal enzyme activity in the transfused blood.
Severe symptoms often manifest within the first several days of life, before newborn screening tests may be finalized. Thus, it is important for the practitioner to maintain a high index of suspicion for inborn errors of metabolism such as galactosemia when the newborn demonstrates feeding intolerance, lethargy, and other suspicious signs like hepatomegaly, renal failure, cataracts, hypoglycemia, and seizures.
If there is a known risk for galactosemia in a fetus, amniocentesis or chorionic villus sampling can make or exclude a diagnosis of galactosemia before delivery.
Postnatal newborn screening is nearly universal in the United States and Europe. However, it should be noted that some populations with the highest incidence of galactosemia also may be less likely to deliver a baby in a hospital setting. In an infant suspected of having galactosemia, GALT enzyme activity in red blood cells or GALT gene analysis should be performed.
Long-term, annual screening of calcium and 25-hydroxyvitamin D is recommended with supplementation as necessary following age-specific recommendations for the general population.
Biochemical monitoring is variable between treatment centers with most common assessments of blood galactose, RBC Gal-1-P and/or urinary galactitol levels though it is unclear whether monitoring these levels is reflective of dietary adherence or correlates with clinical outcomes. Still, Gal-1-P levels are recommended at birth, 3 and nine months and yearly.
Assessment of developmental milestones, intellectual development, and speech and language assessment should be done at regular intervals such as toddler, pre-school, elementary, middle school, and high school ages. Assessment of executive function using a standardized tool is recommended.
Bone density should be assessed using bone densitometry starting around age eight to ten years and repeated every five years or sooner if low bone density is determined.
If cataracts are found, a referral to an ophthalmologist is appropriate.
More than 80% of females with classic galactosemia have primary ovarian insufficiency. This should be discussed before the typical age of puberty and referral to a pediatric endocrinologist is appropriate to discuss the timing and need for hormone testing as well as likely hormone replacement therapy which usually continues until the age of menopause. Males with galactosemia tend to have a normal gonadal function. Counseling regarding reproductive options should be made available to girls with primary ovarian insufficiency.
Treatment is the total elimination of galactose from the diet. In infants, this means cessation of breastfeeding or standard infant formula feeding and transition to non-galactose-containing formula, typically a soy-based, casein hydrolysate, or elemental formula. Change in the diet should be made immediately and should not be delayed to await confirmatory testing. This dietary restriction of galactose is required throughout the lifetime, although some fruits, vegetables, legumes, unfermented soy-based products, and mature cheeses with minimal galactose content may be permissible. Currently, there is no enzyme replacement or other therapy available to allow for safe intake of galactose.
In Duarte variant galactosemia, there is a debate about whether galactose intake should be restricted. Physicians or parents may choose to restrict galactose intake in infancy and early childhood, though the benefits of doing are uncertain.
|||International clinical guideline for the management of classical galactosemia: diagnosis, treatment, and follow-up., Welling L,Bernstein LE,Berry GT,Burlina AB,Eyskens F,Gautschi M,Grünewald S,Gubbels CS,Knerr I,Labrune P,van der Lee JH,MacDonald A,Murphy E,Portnoi PA,Õunap K,Potter NL,Rubio-Gozalbo ME,Spencer JB,Timmers I,Treacy EP,Van Calcar SC,Waisbren SE,Bosch AM,, Journal of inherited metabolic disease, 2017 Mar [PubMed PMID: 27858262]|
|||Lak R,Yazdizadeh B,Davari M,Nouhi M,Kelishadi R, Newborn screening for galactosaemia. The Cochrane database of systematic reviews. 2017 Dec 23; [PubMed PMID: 29274129]|
|||Duarte Variant Galactosemia, Fridovich-Keil JL,Gambello MJ,Singh RH,Sharer JD,,, 1993 [PubMed PMID: 25473725]|
|||Ovarian function in girls and women with GALT-deficiency galactosemia., Fridovich-Keil JL,Gubbels CS,Spencer JB,Sanders RD,Land JA,Rubio-Gozalbo E,, Journal of inherited metabolic disease, 2011 Apr [PubMed PMID: 20978943]|
|||Ovarian tissue cryopreservation and subsequent spontaneous pregnancies in a patient with classic galactosemia., Forges T,Monnier P,Leheup B,Cheillan D,Brivet M,Barbarino A,Guéant JL,Feillet F,, Fertility and sterility, 2011 Jan [PubMed PMID: 20663501]|
|||Gonadal function in male and female patients with classic galactosemia., Rubio-Gozalbo ME,Gubbels CS,Bakker JA,Menheere PP,Wodzig WK,Land JA,, Human reproduction update, 2010 Mar-Apr [PubMed PMID: 19793842]|
|||Bosch AM, Galactosaemia - should it be screened in newborns? Developmental period medicine. 2018; [PubMed PMID: 30281516]|
|||Stroek K,Bouva MJ,Schielen PCJI,Vaz FM,Heijboer AC,de Jonge R,Boelen A,Bosch AM, Recommendations for newborn screening for galactokinase deficiency: A systematic review and evaluation of Dutch newborn screening data. Molecular genetics and metabolism. 2018 May; [PubMed PMID: 29580649]|